NTMT1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from Raji B lymphocytes, featuring targeted disruption of the NTMT1 gene. This loss-of-function model, generated via CRISPR/Cas9-mediated gene disruption, provides a heterogeneous pool of edited cells that collectively ablate NTMT1 expression. The polyclonal format enables robust population-level studies of protein methylation and chromatin regulation, minimizing clonal artifacts. Researchers benefit from a flexible system to examine N-terminal methylation in a lymphoma-relevant context.
The Raji cell line is an Epstein-Barr virus-negative human B lymphoblastoid line originating from a Burkitt’s lymphoma patient. These cells perform antigen presentation, antibody production, and immune surveillance, retaining key pathways of B-cell biology and malignant transformation. Their transformed yet non-virally immortalized nature offers a clinically faithful model for investigating oncogenic mechanisms in aggressive B-cell malignancies.
NTMT1 is an N-terminal methyltransferase that methylates proteins with an Xaa-Pro-Lys motif, regulating their stability, localization, and chromatin association. Key substrates include the chromatin?binding guanine nucleotide exchange factor RCC1 and the oncoprotein SET. NTMT1?mediated methylation of RCC1 enhances its interaction with chromatin, linking methylation status to Ran GTPase signaling and nucleosome dynamics. NTMT1 operates downstream of cell cycle signals and transcriptional regulation and interacts directly with RCC1 and SET. By controlling RCC1 methylation, NTMT1 influences Ran?dependent nuclear transport and mitotic progression; methylation of SET modulates histone chaperone function. Consequently, NTMT1 functions as a critical node coordinating chromatin remodeling, cell cycle progression, and epigenetic regulation.
In Raji cells, NTMT1 knockout disrupts RCC1 and SET methylation, leading to diminished chromatin association of these factors. Loss of RCC1 methylation impairs RanGTP gradient formation, potentially compromising spindle assembly and nucleocytoplasmic transport, while reduced SET methylation may disturb nucleosome assembly. These defects drive chromatin dysregulation and genomic instability, attenuating malignant proliferation. Thus, the knockout model offers a direct means to dissect how N-terminal methylation sustains the aggressive phenotype of B?cell lymphoma.
This product is particularly suited for investigations of protein methylation in lymphoma, including screens for novel NTMT1 substrates and evaluation of NTMT1 as a therapeutic target in B?cell malignancies. Technically, researchers can employ western blotting to assess NTMT1 and substrate methylation status, flow cytometry for cell cycle profiling, chromatin binding assays to quantify RCC1?Cchromatin interactions, proliferation assays, RNA?seq to capture transcriptomic alterations, and immunofluorescence to visualize chromatin structure. These applications support mechanistic studies as well as drug discovery and target validation campaigns. For further technical information, please contact Ascent Research.
